NASDAQ:TBPH - Theravance Biopharma Stock Price, Price Target & More

$22.90 +0.05 (+0.22 %)
(As of 04/19/2018 11:42 AM ET)
Previous Close$22.85
Today's Range$22.44 - $23.70
52-Week Range$22.09 - $43.44
Volume55,581 shs
Average Volume239,654 shs
Market Capitalization$1.33 billion
P/E Ratio-4.19
Dividend YieldN/A
Beta1.81

About Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma logoTheravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. Its product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases. The company's product candidates also comprise Axelopran, an oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trials for opioid induced constipation; Velusetrag (TD-5108), an oral and investigational medicine, which is in Phase II studies for gastrointestinal motility disorders; TD-8954, a selective 5-HT4 receptor agonist for gastrointestinal motility disorders; and TD-1473, a pan-Janus kinase inhibitor, which has completed phase I clinical studies for ulcerative colitis. In addition, it develops TD-0714, a Neprilysin inhibitor that has completed phase I clinical studies for heart failure and chronic kidney diseases; and TD-9855, an investigational norepinephrine and serotonin reuptake inhibitor, which is in Phase II clinical studies for neurogenic orthostatic hypotension. Further, the company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol for the treatment of COPD and asthma; the Inhaled Bifunctional Muscarinic Antagonist-Beta2 Agonist program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TBPH
CUSIPN/A
Phone650-808-6000

Debt

Debt-to-Equity Ratio1.94%
Current Ratio6.05%
Quick Ratio5.79%

Price-To-Earnings

Trailing P/E Ratio-4.19
Forward P/E Ratio-4.97
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.39 million
Price / Sales81.54
Cash FlowN/A
Price / CashN/A
Book Value$2.13 per share
Price / Book10.75

Profitability

EPS (Most Recent Fiscal Year)($5.45)
Net Income$-285,400,000.00
Net Margins-1,855.42%
Return on Equity-136.86%
Return on Assets-55.45%

Miscellaneous

Employees340
Outstanding Shares54,800,000

How to Become a New Pot Stock Millionaire

Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma (NASDAQ:TBPH) released its quarterly earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by $0.49. The biopharmaceutical company had revenue of $4.52 million for the quarter, compared to the consensus estimate of $3.71 million. Theravance Biopharma had a negative return on equity of 136.86% and a negative net margin of 1,855.42%. View Theravance Biopharma's Earnings History.

What price target have analysts set for TBPH?

6 analysts have issued 12-month price objectives for Theravance Biopharma's stock. Their predictions range from $22.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $43.3333 in the next year. View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:
  • 1. Cantor Fitzgerald analysts commented, "Positives from the quarter: 1) An sNDA was filed for the use of Trelegy Ellipta for an expanded indication for the maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD. TBPH is entitled to receive an 85% economic interest in the royalties paid by GSK (Not Covered) on worldwide net sales; 2) Trelegy Ellipta was granted marketing authorization in Europe for the treatment of COPD; 3) in November, TBPH and MYL (Neutral) announced the submission of an NDA for revefenacin (TD-4208) in adults with COPD; 4) at the 2017 Annual CHEST Meeting, TBPH and MYL announced the presentation of additional positive efficacy data from the three- month, pivotal Phase 3 studies of revefenacin (TD-4208); 5) progression of inhaled JAK inhibitor into first-in-human studies in late-2018/early-2019; 6) TBPH expects to provide an update in 1H18 regarding its dialogue with U.S. and EU regulators on Phase 3 requirements for the velusetrag/TD-5108 program in gastroparesis; 7) cash and equivalents totaled ~$390MM at 12/31/17. This excludes the $100MM upfront payment received in February 2018, from the announced collaboration with Janssen (Not Covered)." (2/27/2018)
  • 2. Needham & Company LLC analysts commented, "We recently hosted a series of mtgs w/ investors and Theravance mgmt. TD-1473 JAK inhibitor and GSK respiratory programs were typical starting points for discussion. Mgmt plans to initiate TD-1473 Phase 2b induction/ maintenance trial in Ulcerative Colitis in mid-2018. Initial data from TD-1473 Phase 1b trial in this indication are consistent w/activity in our opinion. Number of doses and patients in Phase 2b trial will depend on data from additional Phase 1b cohorts, which mgmt has not yet seen. GSK launched Trelegy for COPD last month (5.5-8.5% royalty to Theravance). Significant time also spent on TD-9855 and velusetrag, both of which appear on path for Phase 3 initiation in 2018. Reiterate BUY. We believe stock is undervalued ($1.3B EV), given continued maturation of diversified pipeline." (12/5/2017)
  • 3. According to Zacks Investment Research, "Theravance has only one marketed product in its portfolio, Vibativ. Though Vibativ continues to perform well, the company’s sole dependence on the drug for growth is concerning. Moreover, its pipeline programs targeting the therapeutic areas are highly competitive which could affect the company’s operating results. Also, any agreement termination might be a huge setback for the company, as had been the case in the past. However, we are positive on Theravance’s efforts to expand the Vibativ’s label, which, if approved for additional indications, would be commercially significant. Further, Theravance’s collaboration agreement with Mylan for revefenacin, is a big positive. Its shares have outperformed the industry so far this year." (10/10/2017)

Who are some of Theravance Biopharma's key competitors?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 58)
  • Ms. Renée D. Galá, CFO, Sr. VP & Treasurer (Age 46)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. Sharathchandra S. Hegde Ph.D., Sr. VP of Research (Age 54)
  • Dr. Phillip D. Worboys Ph.D., Sr. VP of Translational Science (Age 48)

Has Theravance Biopharma been receiving favorable news coverage?

News stories about TBPH stock have been trending somewhat positive on Thursday, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Theravance Biopharma earned a daily sentiment score of 0.22 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.01 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $22.72.

How big of a company is Theravance Biopharma?

Theravance Biopharma has a market capitalization of $1.33 billion and generates $15.39 million in revenue each year. The biopharmaceutical company earns $-285,400,000.00 in net income (profit) each year or ($5.45) on an earnings per share basis. Theravance Biopharma employs 340 workers across the globe.

How can I contact Theravance Biopharma?

Theravance Biopharma's mailing address is UGLAND HOUSE SOUTH CHURCH STREET, GEORGE TOWN E9, KY1-1104. The biopharmaceutical company can be reached via phone at 650-808-6000 or via email at [email protected]


MarketBeat Community Rating for Theravance Biopharma (TBPH)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  326
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Theravance Biopharma (NASDAQ:TBPH) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Theravance Biopharma in the last 12 months. Their average twelve-month price target is $43.3333, suggesting that the stock has a possible upside of 89.23%. The high price target for TBPH is $55.00 and the low price target for TBPH is $22.00. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.673.00
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.3333$42.8333$42.6667$46.80
Price Target Upside: 89.23% upside52.70% upside59.20% upside38.42% upside

Theravance Biopharma (NASDAQ:TBPH) Consensus Price Target History

Price Target History for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2018Piper JaffrayReiterated RatingOverweight -> Overweight$45.00MediumView Rating Details
2/27/2018Cantor FitzgeraldSet Price TargetBuy$55.00HighView Rating Details
2/8/2018Leerink SwannBoost Price TargetOutperform$45.00 -> $48.00MediumView Rating Details
12/5/2017Needham & Company LLCReiterated RatingBuyHighView Rating Details
11/1/2017Robert W. BairdReiterated RatingSell$22.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageOutperform -> Outperform$45.00MediumView Rating Details
9/19/2016GuggenheimReiterated RatingPositive$40.00N/AView Rating Details
8/3/2016Bank of AmericaDowngradeNeutral -> UnderperformN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Theravance Biopharma (NASDAQ:TBPH) Earnings History and Estimates Chart

Earnings by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ:TBPH) Earnings Estimates

2018 EPS Consensus Estimate: ($4.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($1.40)($1.40)($1.40)
Q2 20181($1.37)($1.37)($1.37)
Q3 20181($0.97)($0.97)($0.97)
Q4 20181($1.02)($1.02)($1.02)

Theravance Biopharma (NASDAQ TBPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018Q4 2017($1.15)($1.64)$3.71 million$4.52 millionViewN/AView Earnings Details
11/7/2017Q3 2017($1.22)($1.27)$3.60 million$4.28 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.13)($1.27)$4.06 million$3.51 millionViewN/AView Earnings Details
5/9/20173/31/2017($1.14)($1.27)$5.07 million$3.09 millionViewListenView Earnings Details
2/27/2017Q416($1.05)($1.36)$5.00 million$5.69 millionViewListenView Earnings Details
11/8/2016Q3 2016($0.95)($0.73)$16.41 million$19.08 millionViewN/AView Earnings Details
8/8/2016Q216($1.05)($1.06)$6.19 million$5.47 millionViewN/AView Earnings Details
5/9/2016Q116($0.96)($1.10)$18.69 million$18.40 millionViewN/AView Earnings Details
3/9/2016Q415($1.62)($1.23)($280,000.00) million$3.90 millionViewN/AView Earnings Details
11/9/2015Q315($1.44)($1.40)$4.24 million$10.70 millionViewN/AView Earnings Details
8/10/2015Q215($1.51)($1.42)$4.25 million$7.10 millionViewListenView Earnings Details
5/7/2015Q1 2015($1.57)($1.29)$7.55 million$20.40 millionViewN/AView Earnings Details
3/10/2015Q414($1.70)($2.02)$2.01 million$1.30 millionViewN/AView Earnings Details
11/6/2014Q3 14($1.85)($1.72)$1.08 million$6.34 millionViewN/AView Earnings Details
8/13/2014($0.56)($1.83)$1.01 million$2.97 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Theravance Biopharma (NASDAQ:TBPH) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Theravance Biopharma (NASDAQ TBPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 85.97%
Insider Trading History for Theravance Biopharma (NASDAQ:TBPH)
Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Theravance Biopharma (NASDAQ TBPH) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2017Bradford J ShaferEVPSell14,670$30.77$451,395.90134,327View SEC Filing  
8/21/2017Frank PasqualoneSVPBuy4,000$26.34$105,360.00213,180View SEC Filing  
8/11/2017Henrietta ForeDirectorBuy6,000$23.99$143,940.0024,000View SEC Filing  
8/11/2017Rick E WinninghamCEOBuy10,000$24.50$245,000.00866,377View SEC Filing  
3/7/2017Brett K HaumannSVPSell424$30.80$13,059.20163,895View SEC Filing  
3/6/2017Brett K HaumannSVPSell13,576$31.52$427,915.52163,895View SEC Filing  
8/25/2016Brett K HaumannSVPSell4,491$27.99$125,703.09188,293View SEC Filing  
8/22/2016Bradford J ShaferEVPSell49,122$27.46$1,348,890.12241,686View SEC Filing  
8/19/2016Brett K HaumannSVPSell9,509$27.97$265,966.73197,391View SEC Filing  
3/14/2016Plc GlaxosmithklineMajor ShareholderBuy1,301,015$23,028,000.00$29,959,773,420,000.00View SEC Filing  
10/7/2015Plc GlaxosmithklineMajor ShareholderBuy44,574$607,544.00$27,080,666,256.00View SEC Filing  
8/18/2015Burton G MalkielDirectorBuy10,000$12.92$129,200.00View SEC Filing  
8/18/2015Junning LeeVPBuy9,000$12.90$116,100.00View SEC Filing  
8/17/2015Renee D GalaCFOBuy10,000$12.18$121,800.00View SEC Filing  
8/17/2015Rick E WinninghamCEOBuy80,000$11.86$948,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Theravance Biopharma (NASDAQ TBPH) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Theravance Biopharma (TBPH) Will Post Quarterly Sales of $5.74 MillionZacks: Analysts Anticipate Theravance Biopharma (TBPH) Will Post Quarterly Sales of $5.74 Million
www.americanbankingnews.com - April 18 at 3:56 AM
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ ConferenceTheravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference
finance.yahoo.com - April 17 at 9:50 AM
Theravance Biopharma (TBPH) Expected to Post Earnings of -$1.29 Per ShareTheravance Biopharma (TBPH) Expected to Post Earnings of -$1.29 Per Share
www.americanbankingnews.com - April 16 at 9:21 AM
Theravance Biopharma (TBPH) Cut to "Sell" at ValuEngineTheravance Biopharma (TBPH) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 8 at 10:47 AM
Theravance Biopharma (TBPH) Upgraded at ValuEngineTheravance Biopharma (TBPH) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 8:56 AM
Theravance Biopharma (TBPH) Given "Sell" Rating at Robert W. BairdTheravance Biopharma (TBPH) Given "Sell" Rating at Robert W. Baird
www.americanbankingnews.com - April 2 at 1:30 PM
Theravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $6.86 MillionTheravance Biopharma Inc (TBPH) Expected to Post Quarterly Sales of $6.86 Million
www.americanbankingnews.com - April 1 at 4:00 AM
Theravance Biopharma Inc (TBPH) Receives Consensus Rating of "Hold" from BrokeragesTheravance Biopharma Inc (TBPH) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 31 at 1:36 AM
Theravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.31 Per ShareTheravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.31 Per Share
www.americanbankingnews.com - March 30 at 1:18 PM
Should You Buy Theravance Biopharma Inc (NASDAQ:TBPH) Now?Should You Buy Theravance Biopharma Inc (NASDAQ:TBPH) Now?
finance.yahoo.com - March 30 at 9:35 AM
Theravance Biopharma (TBPH) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowTheravance Biopharma (TBPH) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 4:26 PM
Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?Theravance Biopharma (TBPH) Down 7.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 29 at 4:26 PM
Theravance Biopharma (TBPH) Coverage Initiated at Piper JaffrayTheravance Biopharma (TBPH) Coverage Initiated at Piper Jaffray
www.americanbankingnews.com - March 29 at 11:16 AM
ValuEngine Lowers Theravance Biopharma (TBPH) to SellValuEngine Lowers Theravance Biopharma (TBPH) to Sell
www.americanbankingnews.com - March 28 at 10:22 PM
Theravance Biopharma (TBPH) Rating Lowered to Strong Sell at BidaskClubTheravance Biopharma (TBPH) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:54 PM
Theravance Biopharma to Present at the 17th Annual Needham Healthcare ConferenceTheravance Biopharma to Present at the 17th Annual Needham Healthcare Conference
finance.yahoo.com - March 21 at 10:40 AM
$6.86 Million in Sales Expected for Theravance Biopharma Inc (TBPH) This Quarter$6.86 Million in Sales Expected for Theravance Biopharma Inc (TBPH) This Quarter
www.americanbankingnews.com - March 15 at 5:43 AM
Zacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) Will Post Earnings of -$1.19 Per ShareZacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) Will Post Earnings of -$1.19 Per Share
www.americanbankingnews.com - March 13 at 9:25 AM
Theravance Biopharma (TBPH) Downgraded by ValuEngine to SellTheravance Biopharma (TBPH) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 11 at 9:02 PM
Theravance Biopharma Inc (TBPH) Given Consensus Rating of "Hold" by BrokeragesTheravance Biopharma Inc (TBPH) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 6 at 1:36 AM
Senzar Asset Management LLC Has $4.79 Million Stake in Theravance Biopharma Inc (TBPH)Senzar Asset Management LLC Has $4.79 Million Stake in Theravance Biopharma Inc (TBPH)
www.americanbankingnews.com - March 5 at 3:44 PM
Woodford Investment Management Ltd Has $227.27 Million Holdings in Theravance Biopharma Inc (TBPH)Woodford Investment Management Ltd Has $227.27 Million Holdings in Theravance Biopharma Inc (TBPH)
www.americanbankingnews.com - March 5 at 2:25 PM
Cantor Fitzgerald Weighs in on Theravance Biopharma Incs FY2018 Earnings (TBPH)Cantor Fitzgerald Weighs in on Theravance Biopharma Inc's FY2018 Earnings (TBPH)
www.americanbankingnews.com - March 5 at 4:46 AM
Leerink Swann Comments on Theravance Biopharma Incs Q1 2018 Earnings (TBPH)Leerink Swann Comments on Theravance Biopharma Inc's Q1 2018 Earnings (TBPH)
www.americanbankingnews.com - March 5 at 1:28 AM
Theravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/YTheravance Biopharma (TBPH) Q4 Loss Wider, Sales Drop Y/Y
finance.yahoo.com - February 28 at 4:58 PM
Cantor Fitzgerald Reiterates Buy Rating for Theravance Biopharma (TBPH)Cantor Fitzgerald Reiterates Buy Rating for Theravance Biopharma (TBPH)
www.americanbankingnews.com - February 27 at 10:48 PM
Theravance Biopharma Inc to Host Earnings CallTheravance Biopharma Inc to Host Earnings Call
finance.yahoo.com - February 27 at 5:01 PM
Theravance Biopharma Q4 Earnings OutlookTheravance Biopharma Q4 Earnings Outlook
finance.yahoo.com - February 27 at 5:01 PM
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - February 27 at 5:01 PM
$3.71 Million in Sales Expected for Theravance Biopharma Inc (TBPH) This Quarter$3.71 Million in Sales Expected for Theravance Biopharma Inc (TBPH) This Quarter
www.americanbankingnews.com - February 26 at 5:50 AM
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial ...Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial ...
www.prnewswire.com - February 21 at 9:35 AM
Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018Theravance Biopharma to Report Fourth Quarter and Full Year 2017 Financial Results on February 27, 2018
finance.yahoo.com - February 20 at 9:07 AM
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to ...Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to ...
www.prnewswire.com - February 16 at 9:09 AM
Theravance Biopharma (TBPH) Highlights Submission of IMPACT Data to EMA to Support Expanded Label for Trelegy ElliptaTheravance Biopharma (TBPH) Highlights Submission of IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
www.streetinsider.com - February 16 at 9:09 AM
Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy ElliptaTheravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta
finance.yahoo.com - February 15 at 8:46 AM
Theravance Biopharma Inc to Post FY2017 Earnings of ($4.96) Per Share, Leerink Swann Forecasts (TBPH)Theravance Biopharma Inc to Post FY2017 Earnings of ($4.96) Per Share, Leerink Swann Forecasts (TBPH)
www.americanbankingnews.com - February 12 at 1:08 AM
Theravance Biopharma (TBPH) Lifted to "Sell" at BidaskClubTheravance Biopharma (TBPH) Lifted to "Sell" at BidaskClub
www.americanbankingnews.com - February 11 at 6:54 AM
Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473
finance.yahoo.com - February 9 at 9:11 AM
Theravance Biopharma Inc (TBPH) Expected to Announce Quarterly Sales of $3.71 MillionTheravance Biopharma Inc (TBPH) Expected to Announce Quarterly Sales of $3.71 Million
www.americanbankingnews.com - February 9 at 3:48 AM
Theravance Biopharma Inc (TBPH) Given Consensus Rating of "Hold" by AnalystsTheravance Biopharma Inc (TBPH) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 9 at 1:48 AM
Commit To Purchase Theravance Biopharma At $22.50, Earn 9.7% Annualized Using OptionsCommit To Purchase Theravance Biopharma At $22.50, Earn 9.7% Annualized Using Options
www.nasdaq.com - February 8 at 4:25 PM
Leerink Swann Boosts Theravance Biopharma (TBPH) Price Target to $48.00Leerink Swann Boosts Theravance Biopharma (TBPH) Price Target to $48.00
www.americanbankingnews.com - February 8 at 10:34 AM
Theravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.15 Per ShareTheravance Biopharma Inc (TBPH) Expected to Announce Earnings of -$1.15 Per Share
www.americanbankingnews.com - February 7 at 11:16 AM
Theravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal DiseasesTheravance Biopharma Enters Global Collaboration with Janssen for TD-1473 in Inflammatory Intestinal Diseases
finance.yahoo.com - February 7 at 9:12 AM
Theravance Biopharma (TBPH) Cut to Strong Sell at BidaskClubTheravance Biopharma (TBPH) Cut to Strong Sell at BidaskClub
www.americanbankingnews.com - February 3 at 10:12 AM
 Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Quarterly Sales of $3.71 Million Analysts Expect Theravance Biopharma Inc (TBPH) Will Post Quarterly Sales of $3.71 Million
www.americanbankingnews.com - January 23 at 8:58 AM
-$1.15 EPS Expected for Theravance Biopharma Inc (TBPH) This Quarter-$1.15 EPS Expected for Theravance Biopharma Inc (TBPH) This Quarter
www.americanbankingnews.com - January 21 at 1:08 PM
Theravance Biopharma (TBPH) Upgraded by BidaskClub to "Sell"Theravance Biopharma (TBPH) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - January 20 at 9:00 AM
Theravance Biopharma Inc (TBPH) Given Average Rating of "Hold" by BrokeragesTheravance Biopharma Inc (TBPH) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - January 15 at 1:38 AM
Zacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.15 Earnings Per ShareZacks: Brokerages Anticipate Theravance Biopharma Inc (TBPH) to Post -$1.15 Earnings Per Share
www.americanbankingnews.com - January 4 at 5:32 PM

SEC Filings

Theravance Biopharma (NASDAQ:TBPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Theravance Biopharma (NASDAQ:TBPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Theravance Biopharma (NASDAQ TBPH) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.